Evidence map›Paper›PMID 24379680›Full record

ArticleOncoTargets and therapy2013

hnRNP C1/C2 and Pur-beta proteins mediate induction of senescence by oligonucleotides homologous to the telomere overhang.

Richard E Mulnix, Ryan T Pitman, Allison Retzer, Ceyda Bertram, Kavin Arasi, Zachary Crees, Jennifer Girard, Srijayaprakash B Uppada, Amanda L Stone, Neelu Puri

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Richard E MulnixDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
Ryan T PitmanDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
Allison RetzerCollege of Medicine, University of Illinois at Chicago, Rockford, IL, USA.
Ceyda BertramDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
Kavin ArasiCollege of Medicine, University of Illinois at Chicago, Rockford, IL, USA.
Zachary CreesCollege of Medicine, University of Illinois at Chicago, Rockford, IL, USA.
Jennifer GirardCollege of Medicine, University of Illinois at Chicago, Rockford, IL, USA.
Srijayaprakash B UppadaDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
Amanda L StoneDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
Neelu PuriDepartment of Biomedical Sciences, University of Illinois at Chicago, Rockford, IL, USA.
University of Illinois Chicago · USUniversity of Illinois Chicago, Rockford campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExperimental disruption of the telomere overhang induces a potent DNA damage response and is the target of newly emerging cancer therapeutics. Introduction of T-oligo, an eleven-base oligonucleotide homologous to the 3'-telomeric overhang, mimics telomere disruption and induces DNA damage responses through activation of p53, p73, p95/Nbs1, E2F1, pRb, and other DNA damage response proteins. ATM (ataxia telangiectasia mutated) was once thought to be the primary driver of T-oligo-induced DNA damage responses; however, recent experiments have highlighted other key proteins that may also play a significant role.

methodsTo identify proteins associated with T-oligo, MM-AN cells were treated with biotinylated T-oligo or complementary oligonucleotide, cell lysates were run on SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and the protein bands observed after treatment of cells with T-oligo or complementary oligonucleotide were analyzed using mass spectrometry. To study the effect of T-oligo on expression of hnRNP C1/C2 (heterogeneous nuclear ribonucleoprotein C1 and C2) and purine-rich element binding proteins (Pur proteins), cells were treated with T-oligo, and immunoblotting experiments were performed. To determine their role in senescence, cells were treated with shRNA (short hairpin ribonucleic acid) against these proteins, and senescence was studied using the senescence associated beta-galactosidase assay.

resultsUsing mass spectrometry, RNA-binding hnRNP C1/C2 and DNA-binding Pur proteins were found to associate with T-oligo. hnRNP C1/C2 exhibited increased expression (3.6-12.0-fold) in non-small-cell lung cancer (NSCLC) and in melanoma cells (4.5-5.2-fold), and Pur proteins exhibited increased expression of 2.2-fold in NSCLC and 2.0-fold in melanoma cells after T-oligo treatment. Experimental knockdown of hnRNP C1/C2 and Pur-beta completely abrogated T-oligo induced senescence in both MU melanoma and H358 NSCLC cells. Additionally, knockdown of Pur-beta prevented T-oligo-induced phosphorylation of p53, hypophosphorylation of pRb, and upregulation of E2F1, p21, and p53.

conclusionThese novel findings highlight proteins essential to T-oligo's anticancer effects that may be of interest in telomere biology and cancer therapeutics.

Indexed as

melanomaNSCLCp21p53pRbT-oligo

Identifiers

PMID24379680
PMCPMC3872271
OpenAlexW2086523009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.